Tamrakar Akhilesh Kumar, Singh Amar Bahadur, Srivastava Arvind Kumar
Central Drug Research Institute, Lucknow, India.
Arch Med Res. 2009 Feb;40(2):73-8. doi: 10.1016/j.arcmed.2008.12.001.
The db/+ mice, which represent the heterozygous counterpart of diabetic db/db mice, are carriers of the mutated gene of the leptin receptor but do not become diabetic at any stage during their lifespan. These mice are being used only for the production of db/db mice. Attempts were made to develop these mice as an alternate in vivo model for antidiabetic drug screening.
Diabetes was induced by injecting streptozotocin, and establishment of diabetic condition was confirmed by measuring blood glucose level, insulin level, body weight, lipid profile, and activity of the key enzymes of carbohydrate metabolism.
Animals showed the characteristics of diabetes throughout the study period and also showed the beneficial effect of the treatment of the gold standard antidiabetic drug metformin that validates these mice as a screening model.
Results showed that streptozotocin-treated db/+ mice can be used as an alternate model in antidiabetic drug discovery research.
db/+小鼠是糖尿病db/db小鼠的杂合对应体，是瘦素受体突变基因的携带者，但在其生命周期的任何阶段都不会患糖尿病。这些小鼠仅用于繁殖db/db小鼠。曾尝试将这些小鼠开发为抗糖尿病药物筛选的替代体内模型。
通过注射链脲佐菌素诱导糖尿病，并通过测量血糖水平、胰岛素水平、体重、血脂谱以及碳水化合物代谢关键酶的活性来确认糖尿病状态的建立。
在整个研究期间，动物表现出糖尿病的特征，同时也显示出金标准抗糖尿病药物二甲双胍治疗的有益效果，这证实了这些小鼠可作为筛选模型。
结果表明，经链脲佐菌素处理的db/+小鼠可作为抗糖尿病药物发现研究的替代模型。
